These final results, together with a preceding report demonstrating that a little-molecule ACKR3 agonist CCX771 reveals anxiolytic-like conduct in mice,two support the concept of targeting ACKR3 as a singular approach to modulate the opioid process, which could open up new therapeutic avenues fo